Findings

What do systematic reviews say?

13 questions · 13 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 23.1%Low 2 · 15.4%Moderate 7 · 53.8%High 1 · 7.7%

Two weeks of AmBd + FLU + steroids vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + FLU + steroids showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (high certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.15 [0.93, 1.42]
1 study · 450 participants
High

Two weeks of AmBd + FLU vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.94 [0.55, 1.62]
3 studies · 371 participants
Low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.37]
1 study · 32 participants
Very low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 2.81 [0.33, 24.16]
1 study · 31 participants
Very low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1 [0.24, 4.23]
1 study · 32 participants
Very low

Two weeks of AmBd + 5FC vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.9 [0.69, 1.19]
4 studies · 538 participants
Low

Two weeks of 5FC + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.85 [0.64, 1.13]
1 study · 339 participants
Moderate

Two weeks of 5FC + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.69, 1.23]
1 study · 340 participants
Moderate

One week of AmBd + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.18 [0.88, 1.58]
1 study · 225 participants
Moderate

One week of AmBd + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.27 [0.94, 1.72]
1 study · 226 participants
Moderate

One week of AmBd + FLU vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU probably leads to higher mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.39 [1.07, 1.8]
1 study · 336 participants
Moderate

One week of AmBd + 5FC vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.58 [0.39, 0.86]
1 study · 227 participants
Moderate

One week of AmBd + 5FC vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.68 [0.47, 0.99]
1 study · 338 participants
Moderate